1. |
Gayen S. Malignant pleural effusion: presentation, diagnosis, and management. Am J Med, 2022, 135(10): 1188-1192.
|
2. |
Bashour SI, Mankidy BJ, Lazarus DR, et al. Update on the diagnosis and management of malignant pleural effusions. Respir Med, 2022, 196: 106802.
|
3. |
Yonar D, Severcan M, Gurbanov R, et al. Rapid diagnosis of malignant pleural mesothelioma and its discrimination from lung cancer and benign exudative effusions using blood serum. Biochim Biophys Acta Mol Basis Dis, 2022, 1868(10): 166473.
|
4. |
Yang Y, Du J, Wang YS, et al. Prognostic impact of pleural effusion in patients with malignancy: a systematic review and meta-analysis. Clin Transl Sci, 2022, 15(6): 1340-1354.
|
5. |
Sorolla MA, Sorolla A, Parisi E, et al. Diving into the pleural fluid: liquid biopsy for metastatic malignant pleural effusions. Cancers (Basel), 2021, 13(11): 2798.
|
6. |
Cheng C, Yang YG, Yang W, et al. The diagnostic value of CEA for lung cancer-related malignant pleural effusion in China: a meta-analysis. Expert Rev Respir Med, 2022, 16(1): 99-108.
|
7. |
Fan X, Liu YQ, Liang ZG, et al. Diagnostic value of six tumor markers for malignant pleural effusion in 1, 230 patients: a single-center retrospective study. Pathol Oncol Res, 2022, 28: 1610280.
|
8. |
Fazli Khalaf F, Asadi Gharabaghi M, Balibegloo M, et al. Pleural CEA, CA-15-3, CYFRA 21-1, CA-19-9, CA-125 discriminating malignant from benign pleural effusions: diagnostic cancer biomarkers. Int J Biol Markers, 2023, 38(2): 81-88.
|
9. |
Lin HX, Ni L. Diagnostic utility of LDH, CA125 and CYFRA21-1 in tuberculosis pleural effusion. Med Clin (Barc), 2022, 158(2): 70-72.
|
10. |
Alam TM, Shaukat K, Hameed A, et al. A novel framework for prognostic factors identification of malignant mesothelioma through association rule mining. Biomedical Signal Processing and Control, 2021, 68: 102726.
|
11. |
Lin LY, Li SG, Xiong Q, et al. A retrospective study on the combined biomarkers and ratios in serum and pleural fluid to distinguish the multiple types of pleural effusion. BMC Pulm Med, 2021, 21(1): 95.
|
12. |
Gao LJ, Wang WJ, Zhang Y, et al. Adenosine deaminase-based measurement in the differential diagnosis of pleural effusion: a multicenter retrospective study. Ther Adv Respir Dis, 2023, 7: 17534666231155747.
|
13. |
Terra RM, Antonangelo L, Mariani AW, et al. Pleural fluid adenosine deaminase (ADA) predicts survival in patients with malignant pleural effusion. Lung, 2016, 194(4): 681-686.
|
14. |
Korczyński P, Mierzejewski M, Krenke R, et al. Cancer ratio and other new parameters for differentiation between malignant and nonmalignant pleural effusions. Pol Arch Intern Med, 2018, 128(6): 354-361.
|
15. |
Verma A, Abisheganaden J, Light RW. Identifying malignant pleural effusion by a cancer ratio (serum LDH: pleural fluid ADA ratio). Lung, 2016, 194(1): 147-153.
|
16. |
张英, 秦江月, 胡雪茹, 等. 活性氧调节因子1联合癌胚抗原诊断恶性胸腔积液的临床研究. 西部医学, 2023, 35(1): 77-81.
|
17. |
刘长力, 闫晓云, 王倩, 等. 内科胸腔镜与CT引导下穿刺活检诊断恶性胸腔积液的价值. 分子影像学杂志, 2023, 46(3): 508-512.
|
18. |
Yang Y, Liu YL, Shi HZ. Diagnostic accuracy of combinations of tumor markers for malignant pleural effusion: an updated meta-analysis. Respiration, 2017, 94(1): 62-69.
|
19. |
Nguyen AH, Miller EJ, Wichman CS, et al. Diagnostic value of tumor antigens in malignant pleural effusion: a meta-analysis. Transl Res, 2015, 166(5): 432-439.
|
20. |
李倩, 叶亮, 杨振华, 等. 胸水CEA与血清CEA比值对恶性胸腔积液的诊断价值. 中国医药科学, 2021, 11(23): 182-185.
|
21. |
Shi HZ, Liang QL, Jiang J, et al. Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis. Respirology, 2008, 13(4): 518-527.
|
22. |
Abrao FC, de Abreu IR, Miyake DH, et al. Role of adenosine deaminase and the influence of age on the diagnosis of pleural tuberculosis. Int J Tuberc Lung Dis, 2014, 18(11): 1363-1369.
|
23. |
Lee SJ, Kim HS, Lee SH, et al. Factors influencing pleural adenosine deaminase level in patients with tuberculous pleurisy. Am J Med Sci, 2014, 348(5): 362-365.
|